ArticleInternational journal of radiation oncology, biology, physics2016
Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.
Article in International journal of radiation oncology, biology, physics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Dose-escalation is needed for gross disease in high-risk neuroblastoma.Pediatric blood & cancer · 2018Trial
- Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical Trial.International journal of radiation oncology, biology, physics · 2026Article
- The role of personalised medicine in treating high-risk neuroblastoma in paediatric patients.Oncology reviews · 2026Review
- Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article.Iranian journal of child neurology · 2025Review
- Role and practical guidelines for the use of radiotherapy in neuroblastoma - a narrative review of literature and clinical trial protocols.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Review
- Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024Article
- Enhancing the sensitization of neuroblastoma to radiotherapy by the construction of a dual-channel parallel free radicals nanoamplifier.Materials today. Bio · 2023Article
- The role of surgery in the treatment of neuroblastoma metastases at rare sites.Journal of cancer research and clinical oncology · 2023Article
- Treatment of High-Risk Neuroblastoma.Children (Basel, Switzerland) · 2023Review
- Long-Term Survival of Neuroblastoma Patients Receiving Surgery, Chemotherapy, and Radiotherapy: A Propensity Score Matching Study.Journal of clinical medicine · 2023Article
- The application and value of radiotherapy at the primary site in patients with high-risk neuroblastoma.The British journal of radiology · 2022Article
- A Phase II Trial of a Personalized, Dose-Intense Administration Schedule ofFrontiers in pediatrics · 2022Article
- Mandibular metastases in neuroblastoma: Outcomes and dental sequelae.Pediatric blood & cancer · 2021Article
- Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry.Frontiers in oncology · 2020Article
- Patterns of recurrence after radiation therapy for high-risk neuroblastoma.Radiation oncology journal · 2019Article
- Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma.Pediatric blood & cancer · 2019Article
- Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.International journal of radiation oncology, biology, physics · 2019Article
- Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?International journal of radiation oncology, biology, physics · 2019Article
- High-Risk Neuroblastoma Treatment Review.Children (Basel, Switzerland) · 2018Review
- Musculoskeletal outcomes and the effect of radiation to the vertebral bodies on growth trajectories for long-term survivors of high-risk neuroblastoma.Journal of radiation oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo evaluate local control after 21-Gy radiation therapy (RT) to the primary site in patients with high-risk neuroblastoma. METHODS AND MATERIALS: After receiving dose-intensive chemotherapy and gross total resection (GTR), 246 patients (aged 1.2-17.9 years, median 4.0 years) with high-risk neuroblastoma underwent RT to the primary site at Memorial Sloan Kettering from 2000 to 2014. Radiation therapy consisted of 21 Gy in twice-daily fractions of 1.5 Gy each. Local failure (LF) was correlated with biologic prognostic factors and clinical findings at the time of diagnosis and start of RT.
resultsMedian follow-up of surviving patients was 6.4 years. Cumulative incidence of LF was 7.1% at 2 years after RT and 9.8% at 5 years after RT. The isolated LF rate was 3.0%. Eighty-six percent of all local failures were within the RT field. Local control was worse in patients who required more than 1 surgical resection to achieve GTR (22.4% vs 8.3%, P=.01). There was also a trend toward inferior local control with MYCN-amplified tumors or serum lactate dehydrogenase ≥1500 U/L (P=.09 and P=.06, respectively).
conclusionAfter intensive chemotherapy and maximal surgical debulking, hyperfractionated RT with 21 Gy in high-risk neuroblastoma results in excellent local control. Given the young patient age, concern for late effects, and local control >90%, dose reduction may be appropriate for patients without MYCN amplification who achieve GTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.